Changes in fatigue of Parkinson's disease during the recurrent COVID‐19 pandemic: Findings from the longitudinal analysis of the PHASE study

IF 3.1 3区医学 Q2 CLINICAL NEUROLOGY

Parkinsonism & related disorders Pub Date : 2024-10-05 DOI:10.1016/j.parkreldis.2024.107161

Hiroshi Kataoka , Keigo Saeki , Yoshiaki Tai , Hitoki Nanaura , Takao Kiriyama , Kazuma Sugie , Kenji Obayashi

{"title":"Changes in fatigue of Parkinson's disease during the recurrent COVID‐19 pandemic: Findings from the longitudinal analysis of the PHASE study","authors":"Hiroshi Kataoka , Keigo Saeki , Yoshiaki Tai , Hitoki Nanaura , Takao Kiriyama , Kazuma Sugie , Kenji Obayashi","doi":"10.1016/j.parkreldis.2024.107161","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>According to Japanese law, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the COVID-19 pandemic falls under Category 2, implying that it necessitates hospitalization, isolation, and significant government participation. The category of infection was lowered to Category 5 in May 2023, meaning that individuals were going back to live their lives as they did before the COVID-19 pandemic.</div><div>This study aimed to explore changes in the prevalence of non-motor symptoms over a longer four-year period, spanning before and after the COVID-19 pandemic.</div></div><div><h3>Methods</h3><div>We conducted a questionnaire survey between January and February in the following years: 2021, 2022, 2023, and 2024.</div></div><div><h3>Results</h3><div>The Parkinson's fatigue scale score in 2021 (mean: 35.3) increased significantly in 2022 (49.84), 2023 (49.33), and 2024 (54.71) (p < 0.001). After adjusting for baseline score using a mixed linear model with random intercept, the Parkinson's fatigue scale was significantly increased by 15.9 points (95 % CI: 10.9 to 20.9) in 2022, 13.1 points (7.9–18.3) in 2023, and 16.9 points (11.3–22.6) in 2024 independently of all potential confounders including other non-motor symptoms.</div></div><div><h3>Conclusions</h3><div>The four years of longitudinal observation during the recurrent COVID-19 pandemic revealed that patients with PD experienced an increase in fatigue. Now, post-COVID-19 fatigue is attracting attention; however, the severity of fatigue may have already deteriorated during the period of recurrent COVID-19 pandemic.</div></div>","PeriodicalId":19970,"journal":{"name":"Parkinsonism & related disorders","volume":"129 ","pages":"Article 107161"},"PeriodicalIF":3.1000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parkinsonism & related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1353802024011738","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

According to Japanese law, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the COVID-19 pandemic falls under Category 2, implying that it necessitates hospitalization, isolation, and significant government participation. The category of infection was lowered to Category 5 in May 2023, meaning that individuals were going back to live their lives as they did before the COVID-19 pandemic.

This study aimed to explore changes in the prevalence of non-motor symptoms over a longer four-year period, spanning before and after the COVID-19 pandemic.

Methods

We conducted a questionnaire survey between January and February in the following years: 2021, 2022, 2023, and 2024.

Results

The Parkinson's fatigue scale score in 2021 (mean: 35.3) increased significantly in 2022 (49.84), 2023 (49.33), and 2024 (54.71) (p < 0.001). After adjusting for baseline score using a mixed linear model with random intercept, the Parkinson's fatigue scale was significantly increased by 15.9 points (95 % CI: 10.9 to 20.9) in 2022, 13.1 points (7.9–18.3) in 2023, and 16.9 points (11.3–22.6) in 2024 independently of all potential confounders including other non-motor symptoms.

Conclusions

The four years of longitudinal observation during the recurrent COVID-19 pandemic revealed that patients with PD experienced an increase in fatigue. Now, post-COVID-19 fatigue is attracting attention; however, the severity of fatigue may have already deteriorated during the period of recurrent COVID-19 pandemic.

查看原文本刊更多论文

在 COVID-19 复发期间帕金森病疲劳的变化：PHASE 研究的纵向分析结果。

背景：根据日本法律，在 COVID-19 大流行期间感染严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）属于第 2 类感染，这意味着必须住院治疗、隔离和政府的大力参与。2023 年 5 月，感染类别降至第 5 类，这意味着个人将回到 COVID-19 大流行之前的生活。本研究旨在探讨 COVID-19 大流行前后四年时间内非运动症状流行率的变化：我们在 2021 年、2022 年、2023 年和 2024 年的 1 月至 2 月期间进行了问卷调查：结果：2021 年帕金森氏症疲劳量表得分（平均值：35.3）在 2022 年（49.84）、2023 年（49.33）和 2024 年（54.71）显著增加（p 结论：在 COVID-19 大流行期间的四年纵向观察中，帕金森氏症疲劳量表得分显著增加：在COVID-19反复流行期间的四年纵向观察显示，帕金森病患者的疲劳感有所增加。现在，COVID-19 后的疲劳问题正引起人们的关注；然而，疲劳的严重程度可能在 COVID-19 复发期间已经恶化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Parkinsonism & related disorders 医学-临床神经学

CiteScore

6.20

自引率

4.90%

发文量

292

审稿时长

39 days

期刊介绍： Parkinsonism & Related Disorders publishes the results of basic and clinical research contributing to the understanding, diagnosis and treatment of all neurodegenerative syndromes in which Parkinsonism, Essential Tremor or related movement disorders may be a feature. Regular features will include: Review Articles, Point of View articles, Full-length Articles, Short Communications, Case Reports and Letter to the Editor.